Citation Report
List of articles citing

Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials

DOI: 10.1186/s12872-018-0757-9
BMC Cardiovascular Disorders, 2018, 18, 24.

#	Paper	IF	Citations
120	How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. **2018**, 20, 255		6
119	Pharmacotherapeutic management of gout in patients with cardiac disease. **2018**, 19, 2011-2018		1
118	[Cardiovascular risk in gout patients : Cardiovascular Safety of Febuxostat or Allopurinol in Participants with Gout and Cardiovascular Comorbidities (CARES)]. **2018**, 59, 1224-1228		
117	Mounting Evidence Indicates That Escalating Doses of Allopurinol Are Unnecessary for Cardiovascular Protection: Comment on the Article by Coburn et al. **2018**, 70, 1696-1697		
116	New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. **2018**, 70, 1702-1709		62
115	Reply. **2018**, 70, 1697-1698		
114	The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis. **2019**, 29, 1011-1022		23
113	Cardiovascular Safety of Urate Lowering Therapies. **2019**, 21, 48		6
112	Cardiovascular Safety of Febuxostat Versus Allopurinol in the Real World: Old Reliable Comes Out on Top. **2019**, 94, 1128-1130		1
111	Vascular Consequences of Hyperuricemia and Hypouricemia. **2019**, 45, 453-464		7
110	Gender differences in association between uric acid and all-cause mortality in patients with chronic heart failure. *BMC Cardiovascular Disorders*, **2019**, 19, 4	2.3	10
109	Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study. **2019**, 71, 1733-1738		14
108	Shortage of Cellular ATP as a Cause of Diseases and Strategies to Enhance ATP. **2019**, 10, 98		43
107	Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients. **2019**, 14, 949-956		20
106	Prognostic value of serum uric acid in patients with acute heart failure: A meta-analysis. **2019**, 98, e14525		17
105	Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis. **2019**, 2019, 1076189		21
104	Gout and cardiovascular disease: crystallized confusion. **2019**, 31, 118-124		20

103	Hyperuricaemia and vascular risk: the debate continues. **2019**, 34, 399-405	9
102	Risk of Acute Myocardial Infarction Among New Users of Allopurinol According to Serum Urate Level: A Nested Case-Control Study. **2019**, 8,	5
101	Que faire devant une hyperuricémie asymptomatique ?. **2019**, 86, 139-146	
100	Xanthine Oxidase Inhibition as a Potential Treatment for Aortic Stiffness in Hypertension. **2019**, 32, 234-236	3
99	The dose-response effects of uric acid on the prevalence of metabolic syndrome and electrocardiographic left ventricular hypertrophy in healthy individuals. **2019**, 29, 30-38	14
98	Heart Failure in Type 2 Diabetes Mellitus. **2019**, 124, 121-141	210
97	Xanthine Oxidase Inhibition by Febuxostat in Macrophages Suppresses Angiotensin II-Induced Aortic Fibrosis. **2019**, 32, 249-256	9
96	How should we manage asymptomatic hyperuricemia?. **2019**, 86, 437-443	19
95	Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users. **2020**, 59, 2340-2349	25
94	Adverse cardiovascular effects of allopurinol are related to the use of high doses. **2020**, 38, 176-177	1
93	Endothelial dysfunction in neuroprogressive disorders-causes and suggested treatments. **2020**, 18, 305	15
92	The TLC-Bioautography as a Tool for Rapid Enzyme Inhibitors detection - A Review. **2020**, 1-19	5
91	Network Meta-Analysis of Drug Therapies for Lowering Uric Acid and Mortality Risk in Patients with Heart Failure. **2021**, 35, 1217-1225	1
90	Hyperuricemia, the heart, and the kidneys - to treat or not to treat?. **2020**, 42, 978-986	9
89	Febuxostat Use and Risks of Cardiovascular Disease Events, Cardiac Death, and All-cause Mortality: Metaanalysis of Randomized Controlled Trials. **2021**, 48, 1082-1089	0
88	Regulation of Vascular Function and Inflammation via Cross Talk of Reactive Oxygen and Nitrogen Species from Mitochondria or NADPH Oxidase-Implications for Diabetes Progression. **2020**, 21,	19
87	Serum metabolic characteristics and biomarkers of early-stage heart failure. **2020**, 14, 119-130	3
86	Drug repurposing in cardiovascular diseases: Opportunity or hopeless dream?. **2020**, 177, 113894	5

85	Revisiting pharmacology of oxidative stress and endothelial dysfunction in cardiovascular disease: Evidence for redox-based therapies. **2020**, 157, 15-37	46
84	Pharmacologic Management of Gout in Patients with Cardiovascular Disease and Heart Failure. **2020**, 20, 431-445	5
83	Cardiovascular events in hyperuricemia population and a cardiovascular benefit-risk assessment of urate-lowering therapies: a systematic review and meta-analysis. **2020**, 133, 982-993	12
82	Uric Acid and Arterial Stiffness. **2020**, 16, 39-54	11
81	Pathological Roles of Mitochondrial Oxidative Stress and Mitochondrial Dynamics in Cardiac Microvascular Ischemia/Reperfusion Injury. **2020**, 10,	51
80	Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial. **2020**, 17, e1003095	17
79	Effect of uric acid levels on mortality in Japanese peritoneal dialysis patients. **2021**, 41, 320-327	7
78	Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. **2021**, 30, 122-130	28
77	Time-dependent changes in plasma xanthine oxidoreductase during hospitalization of acute heart failure. **2021**, 8, 595-604	1
76	Meta-Analysis Assessing the Effects of Allopurinol on Left Ventricular Mass and Other Indices of Left Ventricular Remodeling as Evaluated by Cardiac Magnetic Resonance Imaging. **2021**, 138, 129-132	1
75	Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. **2021**, 3, e58-e70	39
74	Long non-coding RNA LUCAT1 inhibits myocardial oxidative stress and apoptosis after myocardial infarction via targeting microRNA-181a-5p. **2021**, 12, 4546-4555	4
73	Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia. **2021**, 23, 334-344	4
72	Potential natural inhibitors of xanthine oxidase and HMG-CoA reductase in cholesterol regulation: in silico analysis. **2021**, 21, 1	26
71	Urate, Blood Pressure, and Cardiovascular Disease: Evidence From Mendelian Randomization and Meta-Analysis of Clinical Trials. **2021**, 77, 383-392	15
70	Discovery of new therapeutic redox targets for cardioprotection against ischemia/reperfusion injury and heart failure. **2021**, 163, 325-343	15
69	Small-Molecule Inhibitors of Reactive Oxygen Species Production. **2021**, 64, 5252-5275	9
68	Effect of Uric Acid-Lowering Agents on Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. **2021**, 8, 639392	2

67	Allopurinol and cardiovascular events: Time-related biases in observational studies. **2021**,	1
66	Hyperuricemia and Cardiovascular Risk. **2021**, 13, e14855	1
65	Recent developments in predicting CYP-independent metabolism. **2021**, 53, 188-206	1
64	Role of Oxidative Stress in Reperfusion following Myocardial Ischemia and Its Treatments. **2021**, 2021, 6614009	10
63	Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. **2021**, 73, 924-967	73
62	Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection. **2021**, 27, 2112-2130	7
61	Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis. **2021**, 8, 698437	3
60	Effectiveness of Allopurinol in Reducing Mortality: Time-Related Biases in Observational Studies. **2021**, 73, 1749-1757	4
59	Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease. **2021**, 22,	20
58	Uricemia in the acute phase of myocardial infarction and its relation to long-term mortality risk. **2021**, 10, 979-988	
57	Xanthine oxidase inhibitor febuxostat reduces atrial fibrillation susceptibility by inhibition of oxidized CaMKII in Dahl salt-sensitive rats. **2021**, 135, 2409-2422	2
56	Hyperuricemia in Patients With Coronary Artery Disease and Its Association With Disease Severity. **2021**, 13, e17161	0
55	Protective Effects of Linn. and Its Bioactive Compounds on Cardiovascular Organs. **2021**, 12, 725745	2
54	Effects of Hypothermia and Allopurinol on Oxidative Status in a Rat Model of Hypoxic Ischemic Encephalopathy. **2021**, 10,	0
53	Oxidative stress in genetically triggered thoracic aortic aneurysm: role in pathogenesis and therapeutic opportunities. **2021**, 26, 45-52	6
52	Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update. **2021**, 57,	18
51	Berry-Derived Polyphenols in Cardiovascular Pathologies: Mechanisms of Disease and the Role of Diet and Sex. **2021**, 13,	3
50	Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes. **2021**, 21, 499-512	6

49	Soluble Uric Acid Promotes Atherosclerosis via AMPK (AMP-Activated Protein Kinase)-Mediated Inflammation. **2020**, 40, 570-582	33
48	Xanthine oxidase inhibitors in asymptomatic hyperuricemia. **2019**, 13, 137-142	5
47	Hyperuricemia and Cardiovascular Disease. **2019**, 25, 700-709	29
46	Frequency of Hyperuricemia and its Risk Factors in the Adult Population. **2019**, 11, e4198	13
45	Plasma xanthine oxidoreductase is associated with carotid atherosclerosis in stable kidney transplant recipients. **2021**,	
44	Free Radicals and Reactive Oxygen Species in Cardiovascular Pathophysiology: An Overview. **2019**, 403-418	
43	Treatment of gout and hyperuricemia. **2019**, 21, 212-216	
42	Management of Patients with Asymptomatic Hyperuri□mia □to Treat or not to Treat?. **2019**, 25-35	
41	Urate, blood pressure and cardiovascular disease: updated evidence from Mendelian randomization and meta-analysis of clinical trials.	
40	The Impact of Urate-Lowering Therapy in Post-Myocardial Infarction Patients: Insights from a Population-Based, Propensity Score-Matched Analysis. **2021**,	0
39	In-Silico Analysis of Secondary Metabolites that Modulates Enzymes of Cholesterol Target.	
38	Hyperuricemia and the Risk of Heart Failure: Pathophysiology and Therapeutic Implications. **2021**, 12, 770815	4
37	Uric Acid in Inflammation and the Pathogenesis of Atherosclerosis. **2021**, 22,	10
36	Allopurinol to reduce cardiovascular morbidity and mortality: A systematic review and meta-analysis. **2021**, 16, e0260844	3
35	Natural Xanthine Oxidase Inhibitor 5--Caffeoylshikimic Acid Ameliorates Kidney Injury Caused by Hyperuricemia in Mice. **2021**, 26,	0
34	Arterial Hypertension-Oxidative Stress and Inflammation.. **2022**, 11,	7
33	Reduced Risk of Sepsis and Related Mortality in Chronic Kidney Disease Patients on Xanthine Oxidase Inhibitors: A National Cohort Study.. **2021**, 8, 818132	
32	Anthracycline-induced atrial structural and electrical remodeling characterizes early cardiotoxicity and contributes to atrial conductive instability and dysfunction.. **2022**,	0

31	Pharmacological developments in antihypertensive treatment through nitric oxide□GMP modulation. **2022**,		1
30	Serum uric acid level and all-cause and cardiovascular mortality in peritoneal dialysis patients: A systematic review and dose-response meta-analysis of cohort studies.. **2022**, 17, e0264340		2
29	Diabetes mellitus and heart failure: an update on pathophysiology and therapy.. **2022**,		1
28	Role of ATP-Small Heat Shock Protein Interaction in Human Diseases.. **2022**, 9, 844826		0
27	Mechanisms and Clinical Implications of Endothelium-dependent Vasomotor Dysfunction in Coronary Microvasculature.. **2022**,		2
26	U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia.. **2022**, 51, 102271		4
25	U-Shaped Association Between Serum Uric Acid Level and Hypertensive Heart Failure: A Genetic Matching Case-Control Study.. **2021**, 8, 708581		0
24	Synthesis and Antimicrobial, Antiplatelet, and Anticoagulant Activities of New Isatin Deivatives Containing a Hetero-Fused Imidazole Fragment. **2022**, 58, 327-334		
23	Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial.. **2022**, 8,		0
22	Table_1.XLSX. **2019**,		
21	Table_2.XLSX. **2019**,		
20	Table_3.XLSX. **2019**,		
19	Table_4.XLSX. **2019**,		
18	Reactive Oxygen Species Scavenging Nanomedicine for The Treatment of Ischemic Heart Disease.. *Advanced Materials*, **2022**, e2202169	24	9
17	Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions. *Archives of Toxicology*,	5.8	2
16	Exploring medicinal plants for the development of natural enzyme inhibitors. **2022**, 671-690		
15	Cardiovascular protection by SGLT2 inhibitors □do anti-inflammatory mechanisms play a role?. *Molecular Metabolism*, **2022**, 101549	8.8	1
14	Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients. 9,		

13	Using Metabolomics to Identify the Exposure and Functional Biomarkers of Ginger. **2022**, 70, 12029-12040	0
12	Xanthine oxidase inhibition for cardiovascular disease prevention. **2022**, 400, 1172-1173	0
11	RONS and Oxidative Stress: An Overview of Basic Concepts. **2022**, 2, 437-478	6
10	Cardiovascular risk of urate-lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan.	0
9	Effect of low dose allopurinol on glycemic control and glycemic variability in patients with type 2 diabetes mellitus: A cross-sectional study. **2022**, 8, e11549	0
8	Computational study of Piper betle L. phytocompounds by insilico and ADMET analysis for prediction of potential xanthine oxidase inhibitory activity.	0
7	Impact of Allopurinol on early and one-year outcomes of patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized controlled trial.	0
6	In silico discovery of antioxidant peptides from the sea grass Posidonia australis. **2023**, 197-213	0
5	Pharmacometabolomics for the Study of Lipid-Lowering Therapies: Opportunities and Challenges. **2023**, 24, 3291	0
4	U-shaped association of serum uric acid with cardiovascular disease risk scores and the modifying role of sex among Chinese adults. **2023**,	0
3	Novel Reversible Inhibitors of Xanthine Oxidase Targeting the Active Site of the Enzyme. **2023**, 12, 825	0
2	Advances in pharmacotherapies for hyperuricemia. **2023**, 24, 737-745	0
1	Xanthine oxidase inhibition and cardiovascular protection: Don't shoot in the dark. **2023**,	0